354 Autoimmune Hepatitis Misdiagnosed as Hepatitis C Responding to Interferon/Ribavirine Therapy

نویسندگان

  • Michal R. Pijak
  • Veronika Csibova
چکیده

351 Prevalence of Thyroid Peroxidase Autoantibodies (ANTI-TPO) in Women with Autoimmune Connective Tissue Diseases (ACTD) Georgios Papadopoulos, MD, Anastasia Vakaloudi, PhD, Eirene Koutsika, MD, Ekarerini Anastasiou, MD, and Asimoula Koteli, MD. Immunology Laboratory, General Hospital Agios Pavlos, Thessaloniki, Greece. Background: Chronic autoimmune thyroiditis, manifested by positive test for antithyroid antibodies, is common in the general population, occurring in 10 to 20 percent of women. The aim of the study was to determine whether Anti-TPO is more prevalent in women with ACTD, compared to the general population. Methods: Anti-TPO was determined in 290 women diagnosed with ACTD based on ACR (American College of Rheumatology) criteria and in 50 healthy women (control group). Among ACTD patients, 121 were diagnosed with Rheumatoid Arthritis (RA), 44 Systemic Lupus Erythematosus (SLE), 43 Sjogren’s Syndrome (SS), 42 Systemic Scleroderma (SScl) and 40 Psoriatic Arthritis (PsA). Anti-TPO was measured by Chemiluminescent Microparticle Immunoassay (CMIA) on Architect i2000SR (ABBOT Laboratories). Results: The prevalence of Anti-TPO in separate groups of patients had as follow: RA 28.93%, SLE 29.55%, SS 27.91%, SScl 23.81%, PsA 30% and control group 12%. Conclusions: ACTD and thyroid autoimmune diseases often overlap with each other. Increased Anti-TPO may be most common among women patients with ACTD. On the other hand, these systemic diseases are often present in Hasimoto’s thyroiditis subjects. Therefore it is clinically important to screen women patients with ACTD for the co-existence of thyroid disorders.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Vitiligo Complicating chronic Hepatitis B patients treated with α-Interferon (Report of two cases)

α-Interferon is an antiviral agent used in treatment of chronic hepatitis B. Triggering of the underlying autoimmune disease or exacerbation of pre-existing auto immune disease is documented with α-interferon, but there are few reports about occurrence of autoimmune disorders such as systemic lupus erythematosus, Vitiligo, hypo and hyperthyroidism after administration of α-interferon in the lit...

متن کامل

Severe muscle weakness during treatment with pegylated interferon alfa for chronic hepatitis C virus infection A rare complication

Background: Interferons (IFNs) are common therapeutics for several diseases such as viral hepatitis, multiple sclerosis and malignancy. A variety of autoimmune related side effects have been observed during IFN therapy. Rare cases of myopathy, polymyositis or dermatomyositis have been reported during therapy with high doses of IFN^5. Case Presentation: In this report, we describe a case with se...

متن کامل

A MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF HEBER ON (INTERFERON ALFA-2b) IN COMBINATION WITH RIBAVIRIN FOR THE TREATMENT OF CHRONIC HEPATITIS C IN IRAN

 ABSTRACT Background: Combination therapy with interferon and ribavirin is the most effective treatment for chronic hepatitis C today. The aim of this study was to evaluate the efficacy and safety of thrice-weekly Heberon (interferon alfa-2b) in combination with ribavirin as first -line treatment of chronic hepatitis C. Methods: A total of97 treatment-naive patients received Heberon three milli...

متن کامل

Interferon Resistance of Hepatitis C Virus Genotypes 1a/1b: Relationship to Structural E2 Gene Quasispecies Mutations

Hepatitis C virus (HCV) envelope glycoprotein-2 (E2) inhibits the interferon (IFN)–induced, double –stranded RNA activated protein kinase (PKR) via PKR eukaryotic initiation factor-2α phosphorylation homology domain (PePHD). Present study examined the genetic variability of the PePHD in patients receiving interferon therapy. The PePHD region from HCV genotype 1a/1b infected patients receiving I...

متن کامل

EFFICACY AND SAFETY OF COMBINATION THERAPY OF INTERFERON-ALPHA 2B PLUS RIBAVIRIN FOR CHRONIC HEPATITIS C

Introduction: The aim of this study is to assess the therapeutic efficacy and safety of a particular brand of IFN alpha (PDferon B®) in combination with ribavirin (RlBA) on Iranian patients with chronic hepatitis C (CHC). The addition of RIBA to the standard treatment with interferon (IFN) alpha led to an improvement in sustained virologic response (SVR) from less than 20% with IFN monother...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 5  شماره 

صفحات  -

تاریخ انتشار 2012